Otonomy to Host Pipeline Program Update Conference Call and Webcast

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will host a conference call and webcast on June 15, 2020, at 4:30 p.m. EDT to discuss the status of its ongoing clinical trials, including the Phase 3 trial of OTIVIDEX^® for Ménière’s disease. This update follows a delay in April due to COVID-19. Interested parties can access the call by dialing (877) 305-6769 domestically or (678) 562-4239 internationally, using conference ID 3655435. The call will also be available via webcast on Otonomy’s website, archived for 30 days.

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the company’s three ongoing clinical trials including the Phase 3 trial of OTIVIDEX^® in Ménière’s disease at 4:30 p.m. EDT / 1:30 p.m. PDT on June 15, 2020. This call is consistent with Otonomy’s previously announced plan to provide an update on the timing guidance, which had been pulled in April as a result of the COVID-19 pandemic. 

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3655435. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What is the date and time of Otonomy's conference call regarding OTIVIDEX?

Otony's conference call will take place on June 15, 2020, at 4:30 p.m. EDT.

What will Otonomy discuss during the conference call?

Otonomy will discuss the status and timeline of its ongoing clinical trials, including the Phase 3 trial of OTIVIDEX for Ménière’s disease.

How can I access the Otonomy conference call?

The conference call can be accessed by dialing (877) 305-6769 for domestic calls or (678) 562-4239 for international callers, using conference ID 3655435.

Where can I find the webcast of the Otonomy conference call?

The live webcast will be available in the investor relations section of Otonomy's website and archived for 30 days.

Why was the timing guidance for Otonomy's clinical trials pulled?

The timing guidance was initially pulled in April due to the COVID-19 pandemic.